Buy
Sell
Share Name Share Symbol Market Type
Antibe Therapeutics Inc TSX:ATE Toronto Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.01 1.67% 0.61 0.61 0.62 0.61 0.60 0.61 19,600 19:33:56

Antibe Therapeutics to Present at Upcoming Virtual Investor Conferences

07/06/2021 12:00pm

Business Wire


Antibe Therapeutics (TSX:ATE)
Historical Stock Chart


From Jul 2020 to Jul 2022

Click Here for more Antibe Therapeutics Charts.

Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies for a wide range of inflammatory conditions, today announced its participation in the following U.S.-based virtual investor conferences in June:

2021 LD Micro Invitational XI, Live company presentation by Scott Curtis, Executive VP, and Dr. Joseph Stauffer, Chief Medical Officer, on Wednesday, June 9, 2021 at 12:30 pm (Eastern Time).

Raymond James Human Health Innovation Conference, Live company presentation by Dan Legault, CEO, and Dr. Joseph Stauffer on Wednesday, June 23, 2021 at 8:40 am (Eastern Time).

A link to the webcast of each event will be available on the News and Events section of the Company’s website at antibethera.com. Following the presentations, a replay of the webcasts will be available on the website for 90 days.

About Antibe Therapeutics Inc.

Antibe is leveraging its proprietary hydrogen sulfide platform to develop next-generation safer therapies to address inflammation arising from a wide range of medical conditions. The Company’s current pipeline includes three assets that seek to overcome the gastrointestinal (“GI”) ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (“NSAIDs”). Antibe’s lead drug, otenaproxesul, is entering Phase III for the treatment of osteoarthritis pain. Additional assets under development include a safer alternative to opioids for peri-operative pain, and a GI-protective alternative to low-dose aspirin. The Company’s next target is inflammatory bowel disease (“IBD”), a condition long in need of safer, more effective therapies. Learn more at antibethera.com.

Antibe Therapeutics Inc. Christina Cameron VP Investor Relations +1 416-577-1443 christina@antibethera.com

1 Year Antibe Therapeutics Chart

1 Year Antibe Therapeutics Chart

1 Month Antibe Therapeutics Chart

1 Month Antibe Therapeutics Chart
ADVFN Advertorial
Your Recent History
TSX
ATE
Antibe The..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20220702 08:56:05